England's NHS Delays Routine Offering of Puberty-Blocking Drugs To Minors, Calls for More Evidence

In a significant development, the publicly funded National Health Service in England, the NHS, has announced a delay in routinely offering puberty-blocking drugs to minors at gender identity clinics.

The decision comes as the NHS seeks more evidence about the potential benefits and harms associated with these drugs.

The move has sparked discussions and debates about the appropriate course of action when it comes to gender-affirming care for children.

NHS Temporarily Suspends Routine Prescription of Puberty-Blocking Drugs

According to the New York Post, the National Health Service in England issued a statement on Friday, June 9, revealing that outside of a research setting, puberty-suppressing hormones should not be routinely commissioned for children and adolescents.

This decision signifies a shift in the NHS's approach to the administration of puberty-blocking drugs, emphasizing the need for further research and evidence before proceeding.

The NHS, however, clarified that minors could still be considered for such treatment in exceptional circumstances.

As part of the NHS's reevaluation of its approach to gender identity clinics, four new regional clinics are set to open later this year.

These clinics will replace the renowned Gender Identity Development Service in London, which was previously the sole facility of its kind in England.

The decision to shut down the London service was based on a review that highlighted its increasing burden and insufficient evidence regarding treatment outcomes.

The introduction of new clinics aims to distribute the workload more evenly across the country and provide better access to gender-affirming care for minors.

While the issue of gender-affirming care for children in Britain is not as heated as it is in the United States, where several Republican-led states have banned puberty blockers and other treatments for transgender minors, it has been the subject of both political and legal battles.

The NHS's decision to delay routine prescription of puberty-blocking drugs has received mixed reactions.

Advocates argue that the move is responsible, allowing for a more thorough evaluation and consideration of potential risks and benefits.

On the other hand, critics express concerns about the impact on vulnerable minors, who may experience delays in accessing necessary treatment.

As reported by The New York Times, after receiving public feedback for several months, the NHS has officially implemented a new policy change.

The draft of this policy was initially released in October, and now, with Friday's announcement, it has been formally established. The policy is set to take effect later this year.

Read Also: 13-Year-Old Shark Attack Survivor Joins Researchers on Shark Tagging Expedition

Calls for More Evidence and Ongoing Research

According to the BBC, the new Children and Young People's Gender Dysphoria Research and Oversight Board will conduct a clinical study to examine the effects of puberty-blocking drugs.

The study, slated to commence in 2024, aims to investigate the impact of these drugs on children and young people with early-onset gender dysphoria.

Dr. Hilary Cass identified the service as "unsustainable" and emphasized the need for a new care model.

It was noted that many children referred to the service have complex needs, including a significant proportion with autism or other types of neurodiversity.

The NHS acknowledges that a considerable number of young people with gender-related concerns may also experience additional challenges related to mental health, neurodevelopment, and family or social matters.

The new service will adopt a holistic approach, focusing on the unique needs of each child and conducting careful therapeutic exploration.

The review highlighted the need for more comprehensive evidence before establishing clear guidelines on the use of puberty-blocking drugs.

The NHS emphasized that doctors at the new clinics will still have the ability to prescribe puberty blockers on an exceptional, case-by-case basis, subject to approval from a national team of medical experts.

While the decision does not prohibit children and their families from seeking puberty blockers elsewhere, the NHS strongly discourages this approach.

Additionally, the NHS recognized that the adoption of the new policy would necessitate the discontinuation of the requirement for young people to take puberty blockers for a specified duration before receiving hormone treatments.

This adjustment aligns with the evolving understanding of gender-affirming care and aims to streamline the treatment process.

Related Article: How To Protect Children From Unhealthy Air Quality